drugset / Trial / NCT07109323
Autologous Transplantation Combined With BCMA CAR-T in the Treatment of UHR-MM
Phase 1/2
Recruiting
50 enrolled
Institute of Hematology & Blood Diseases Hospital, China
Hebei Taihe Chunyu Biotechnology Co., Ltd · collab
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the safety and efficacy of autologous hematopoietic stem cell transplantation (ASCT) combined with BCMA-CART in the treatment of UHR-MM.
Timeline
- Start
- 2025-03-03
- Primary completion
- 2028-03-02
- Completion
- 2030-03-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BCMA CAR-T | Cell therapy | 1e+06 cells/kg | Other |
| Subject | BCMA CAR-T | Cell therapy | 2e+06 cells/kg | Other |